All Programs

Use the tool below to view all available Global Oncology Academy Series

Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Lunning, DO, FACP
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Clinician's Roundtable
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
- Charles Turck, PharmD, BCPS, BCCCP
- Brennan Spiegel, MD, MSHS
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
- Ryan Quigley
- David F. McDermott, MD
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
- Richard Kim, MD
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
- Jorge Nieva, MD
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
- Jorge Nieva, MD
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
- Vanessa Helou, MD
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Project Oncology®
Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
Global Oncology Academy
Active Surveillance of Prostate Cancer: Evaluating Long-Term Outcomes
- Lisa Newcomb, PhD
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Global Oncology Academy
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
- Lisa Newcomb, PhD
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Project Oncology®
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
Project Oncology®
Poster Pearl: Axatilimab’s Impact on Fibrosis-Dominant Organs in cGVHD
- Charles Turck, PharmD, BCPS, BCCCP
- Daniel Wolff, MD
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
Global Oncology Academy
Redefining mHSPC Treatment: From Monotherapy to Triplet Therapy Regimens
- Daniel J. George, MD
ADT Monotherapy for mHSPC: How to Identify the Right Patients
ADT Monotherapy for mHSPC: How to Identify the Right Patients
Global Oncology Academy
ADT Monotherapy for mHSPC: How to Identify the Right Patients
- Daniel J. George, MD

All Programs

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

All Programs

Popular

Title

Share on ReachMD

Welcome to the newGlobal Oncology Academy website.

Welcome to the new
Global Oncology Academy website.